Extranodal Natural Killer T-cell Lymphoma Nasal Type

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma [Phase 2]

  A Phase 2 randomized trial is evaluating sintilimab in combination with the P-GEMOX regimen versus P-GEMOX alone for advanced extranodal nat…

• CLINICAL_TRIALS research · 2025-07-20
  Clinical Trial Update: Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas [Phase 1]

  Phase 1 clinical trial evaluating allogeneic CD30.CAR-EBVSTs in relapsed or refractory CD30-positive lymphomas, currently recruiting.

• CLINICAL_TRIALS research · 2025-07-14
  Clinical Trial Update: "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating the combination of selinexor, pegaspargase, and dexamethasone for extranodal natural killer/T-cell lym…

• CLINICAL_TRIALS research · 2025-03-13
  Clinical Trial Update: A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) [Phase 3]

  A multicenter Phase 3 randomized trial evaluates adding toripalimab to sequential chemoradiotherapy versus chemoradiotherapy alone in newly …

• CLINICAL_TRIALS research · 2025-02-10
  Clinical Trial Update: Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) [Phase 2]

  Phase II clinical trial evaluating the combination of golidocitinib and benmelstobart in relapsed/refractory extranodal natural killer/T-cel…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2024-08-27
  Clinical Trial Update: Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL [Phase 2]

  Phase 2 clinical trial update evaluating selinexor combined with an anti-PD-1 antibody and the Pegaspargase-Gemcitabine-Oxaliplatin regimen …

• CLINICAL_TRIALS research · 2017-02-16
  Clinical Trial Update: Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma [Phase 2]

  This document updates a Phase II clinical trial evaluating the combination of durvalumab and lenalidomide for relapsed/refractory extranodal…

• CLINICAL_TRIALS research · 2017-02-13
  Clinical Trial Update: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma [NA]

  This clinical trial update describes evaluating 18F-FDG PET/CT with liver SUVmax-based criteria to prognosticate outcomes in patients with e…

• CLINICAL_TRIALS research · 2015-07-17
  Clinical Trial Update: Treatment of Natural Killer/T Cell Lymphoma-I/II [Phase 4]

  An update on a Phase 4 study evaluating treatment for extranodal natural killer/T-cell lymphoma, nasal type. The current trial status is unk…